- Home
- LH vs ZBH Comparison
LH vs ZBH Comparison
Compare LH & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LH | ZBH |
|---|---|---|
| Founded | 1971 | 1927 |
| Country | United States | United States |
| Employees | 70000 | N/A |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.6B | 19.5B |
| IPO Year | 2005 | 2001 |
Fundamental Metrics
Financial Performance| Metric | LH | ZBH |
|---|---|---|
| Price | $261.28 | $93.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 19 |
| Target Price | ★ $311.33 | $104.76 |
| AVG Volume (30 Days) | 493.4K | ★ 1.8M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.05% | 1.03% |
| EPS Growth | ★ 18.33 | N/A |
| EPS | ★ 10.46 | 3.55 |
| Revenue | ★ $13,951,700,000.00 | $8,231,500,000.00 |
| Revenue This Year | $8.30 | $4.97 |
| Revenue Next Year | $4.79 | $3.75 |
| P/E Ratio | ★ $26.14 | $26.18 |
| Revenue Growth | ★ 7.25 | 7.20 |
| 52 Week Low | $209.38 | $84.59 |
| 52 Week High | $293.72 | $108.29 |
Technical Indicators
Market Signals| Indicator | LH | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 57.09 |
| Support Level | $259.23 | $89.16 |
| Resistance Level | $270.72 | $95.33 |
| Average True Range (ATR) | 6.70 | 1.78 |
| MACD | 0.34 | 0.59 |
| Stochastic Oscillator | 9.93 | 88.52 |
Price Performance
Historical ComparisonAbout LH Laboratory Corporation of America Holdings
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.